Advent Access, a Singapore-based medtech company, closed a S$2.6m pre-Series A financing.
The financing was led by Accuron MedTech.
The company intends to use the funds to advance the development and commercialization of its patented av-Guardian™ technology for vascular access in dialysis patients, towards a filing for CE mark registration within the next 18 months.
Led by Peh Ruey Feng, Founder and Chief Executive Officer, Advent Access has developed the av-Guardian™, a device-guided needling platform that engineers a high-quality tissue track to enable reliable and less-painful vascular access to the arteriovenous fistula (AV fistula) commonly used by dialysis patients. The av-Guardian™ has pioneered the concept of a “guardian guide-door” to the AV fistula that is non-invasive to the vessel, reducing wear and tear on the dialysis patient’s vein and resulting in a reduction in hospitalisation and surgery.
Advent is a spin-off from the Agency for Science, Technology and Research (A*STAR). The company has been working with ETPL, the commercialization arm of A*STAR, in technology productisation and clinical validation.